Method for analyzing related substances of domperidone intermediate DP-2
The detection of domperidone intermediate DP-2 by high performance liquid chromatography solved the problem of difficulty in controlling impurities during domperidone synthesis, realized qualitative and quantitative analysis of warning structural impurities, and improved the safety and effectiveness of the drug.
Patent Information
- Application Number
- CN202411232625.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-04
- Publication Date
- 2024-11-29
AI Technical Summary
In the prior art, it is difficult to control impurities during the synthesis of domperidone, which may lead to side reactions and genotoxic impurities residues, affecting the safety and effectiveness of the drug, and lack of effective detection methods.
Using high performance liquid chromatography, the preparation of diluent and the preparation of test sample solution, combined with the gradient elution procedure, the Waters XBridge C18 chromatography column and ammonium acetate aqueous solution were used as the mobile phase, and the detection wavelength was 280nm and the flow rate was 1.0mL/ Min, column temperature was 30°C, and injection volume was 10 μL. Qualitative and quantitative analysis of domperidone intermediate DP-2 was performed.
It provides a detection method with high sensitivity and accuracy, which can qualitatively and quantitatively analyze impurities in DP-2, especially potential genotoxic impurities in warning structures, ensure the quality of intermediates and improve the safety and effectiveness of the finished product.
Smart Images

Figure CN119044362A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of chemical drug analysis, and particularly relates to an analysis method for related substances of a domperidone intermediate DP-2. Background Art
[0002] In the domperidone synthesis method disclosed in the prior art, 1-(3-chloropropyl)-benzimidazol-2-one (DP-2 for short) is an important intermediate for the synthesis of domperidone, and its molecular formula is C 10 H 11 ClN2O, molecular weight 210.66, chemical structure is as follows:
[0003]
[0004] Patent CN201711479448.6 discloses a method for synthesizing 1-(3-chloropropyl)-benzimidazol-2-one. The background technology of the patent points out that 1-(3-chloropropyl)-benzimidazol-2-one is a key intermediate of domperidone, and its purity and industrial cost directly affect the product quality. Reducing the content of by-products / impurities has important economic significance; Patent CN201610815949.6 discloses a method for synthesizing 1-(3-chloropropyl)-benzimidazol-2-one, a domperidone drug intermediate; Patent CN201510995506.5 also discloses a method for synthesizing 1-3-(chloropropyl)-benzimidazol-2-one, a domperidone drug intermediate. At present, the existing technologies are basically centered on the synthesis of 1-(3-chloropropyl)-benzimidazol-2-one, and there are few studies on the detection methods of 1-(3-chloropropyl)-benzimidazol-2-one related substances.
[0005] If the impurities introduced during the synthesis of domperidone are not effectively controlled, they will cause side reactions, especially genotoxic impurities with warning structures, which may remain in the finished product and directly affect the safety and effectiveness of the drug.
[0006] Therefore, in order to control the quality of drugs and improve the safety of drugs, it is necessary to develop a simple and accurate method for detecting related substances of domperidone intermediate DP-2. Summary of the invention
[0007] The technical problem to be solved by the present invention is to provide a method for analyzing related substances of domperidone intermediate DP-2 in view of the deficiencies of the above-mentioned prior art.
[0008] In order to solve the above technical problems, the technical solution adopted by the present invention is: a method for analyzing related substances of domperidone intermediate DP-2, characterized in that the method comprises the following steps:
[0009] Step 1: Solution preparation:
[0010] Preparation of diluent: Mix purified water and methanol in a volume ratio of 60:40 to obtain a diluent;
[0011] Preparation of test solution: Weigh the domperidone intermediate DP-2, dissolve it in diluent and dilute it to make a 2 mg / mL test solution;
[0012] Preparation of control solution: dilute with diluent to prepare a control solution containing 20 μg / mL of domperidone intermediate DP-2;
[0013] Step 2, high performance liquid chromatography determination: accurately measure the test solution and the control solution obtained in step 1, respectively, inject them into the high performance liquid chromatograph for detection, and record the chromatogram. The specific chromatographic conditions are:
[0014] Chromatographic column: C18;
[0015] Detection wavelength: 280nm;
[0016] Mobile phase: ammonium acetate aqueous solution as mobile phase A, methanol as mobile phase B;
[0017] Flow rate: 0.8mL / min~1.2mL / min;
[0018] Column temperature: 28℃~32℃;
[0019] Injection volume: 10 μL.
[0020] The above-mentioned method for analyzing related substances of a domperidone intermediate DP-2 is characterized in that the chromatographic conditions in step 2 are:
[0021] Chromatographic column: Waters XBridge C18, length 250 mm, inner diameter 4.6 mm, filler particle size 5 μm;
[0022] Detection wavelength: 280nm;
[0023] Mobile phase: 0.5% ammonium acetate aqueous solution as mobile phase A, methanol as mobile phase B;
[0024] Flow rate: 1.0 mL / min;
[0025] Column temperature: 30°C;
[0026] Injection volume: 10 μL.
[0027] The above-mentioned method for analyzing related substances of the domperidone intermediate DP-2 is characterized in that the detection in step 2 adopts the following procedure of gradient elution:
[0028] Time (min) Mobile phase A volume content (%) Volume content of mobile phase B (%) 0 55 45 10 45 55 35 35 65 37 35 65 38 55 45 45 55 45 .
[0029] Compared with the prior art, the present invention has the following advantages:
[0030] 1. The present invention provides a method for detecting related substances of domperidone intermediate DP-2. The blank solvent has no interference, good specificity, high sensitivity and accuracy, and provides an effective method for detecting related substances of domperidone intermediate DP-2.
[0031] 2. The method for detecting related substances of the domperidone intermediate DP-2 provided by the present invention can qualitatively and quantitatively analyze the impurities in DP-2, especially the potential genotoxic impurities DP-2-ZZ-01, DP-2-ZZ-02, and DP-2-ZZ-05 containing warning structures, provide a direction for the control of impurities, ensure the quality of the intermediate, and improve the safety and effectiveness of the finished product.
[0032] The technical solution of the present invention is further described in detail below through the accompanying drawings and embodiments. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 It is the HPLC chromatogram of blank solution.
[0034] Figure 2 is the HPLC chromatogram of the system suitability solution.
[0035] Figure 3 It is the HPLC chromatogram of the test solution.
[0036] Figure 4 It is the HPLC chromatogram of the self-reference solution. DETAILED DESCRIPTION
[0037] The structures, names and reference substances of the drugs, reagents, instruments and impurities used in Example 1 and the methodological verification of the present invention are shown in Tables 1 to 4 below.
[0038] Table 1 Drugs and reagents
[0039] Reagents level source DP-2 / self made Methanol Chromatographic grade Fisher Ammonium acetate Analytical level Maclean Purified water / self made
[0040] Table 2 Instrument information
[0041] instrument model factory High performance liquid chromatography Agilent 1260infinityⅡ Agilent Technologies Electronic balance MS105 METTLER TOLEDO
[0042] Table 3 Impurity structure
[0043]
[0044]
[0045] Table 4 Reference substance information
[0046]
[0047]
[0048] Example 1
[0049] This embodiment includes the following steps:
[0050] Step 1: Solution preparation:
[0051] Preparation of diluent: Mix purified water and methanol in a volume ratio of 60:40 to obtain a diluent;
[0052] Preparation of test solution: Weigh the domperidone intermediate DP-2, dissolve it in diluent and dilute it to make a 2 mg / mL test solution;
[0053] Preparation of control solution: Accurately pipette the test solution and dilute it with diluent to prepare a control solution containing 20 μg / mL of domperidone intermediate DP-2;
[0054] Step 2: HPLC determination: Accurately measure the test solution and control solution prepared in step 1 and inject them into the HPLC instrument for detection, and record the chromatogram, see Figure 3 and Figure 4 , the specific chromatographic conditions are:
[0055] Chromatographic column: Waters XBridge C18, length 250 mm, inner diameter 4.6 mm, filler particle size 5 μm;
[0056] Detection wavelength: 280nm;
[0057] Mobile phase: 0.5% ammonium acetate aqueous solution as mobile phase A, methanol as mobile phase B;
[0058] Flow rate: 1.0 mL / min;
[0059] Column temperature: 30°C;
[0060] Injection volume: 10 μL;
[0061] The detection procedure using gradient elution is as follows:
[0062] Table 5 Gradient elution program
[0063]
[0064]
[0065] In this example, three batches of DP-2 (batch numbers: DP20201001T06, DP20201002T06, DP20201003T06) were tested for related substances, and high performance liquid chromatograms were recorded. The analysis results of the related substances of DP-2 obtained are shown in Table 6 below:
[0066] Table 6 Test results of related substances of three batches of DP-2
[0067]
[0068] As shown in Table 6, the test results of relevant substances of the three batches of DP-2 all meet the requirements.
[0069] A methodological investigation was conducted on the detection method of the domperidone intermediate-related substances of the present invention, and the specific process and results are as follows.
[0070] 1. Exclusive inspection
[0071] (1) Solution preparation
[0072] Blank solution: Take methanol-purified water (volume ratio of 40:60) as the blank solution.
[0073] DP-1 stock solution (100 times): Accurately weigh 4 mg of DP-1 reference substance, place it in a 10 mL volumetric flask, add methanol to dissolve and dilute to the scale, shake well, and obtain.
[0074] DP-2-ZZ-01 stock solution (100 times): Accurately weigh 3 mg of DP-2-ZZ-01 reference substance, place it in a 10 mL volumetric flask, add methanol to dissolve and dilute to the scale, shake well, and obtain.
[0075] DP-2-ZZ-02 stock solution (100 times): Accurately weigh 15 mg of DP-2-ZZ-02 reference substance, place it in a 50 mL volumetric flask, add methanol to dissolve and dilute to the scale, shake well, and obtain.
[0076] DP-2-ZZ-04 stock solution (100 times): Accurately weigh 6 mg of DP-2-ZZ-04 reference substance, place it in a 10 mL volumetric flask, add methanol to dissolve and dilute to the scale, shake well, and obtain.
[0077] DP-2-ZZ-05 stock solution (100 times): Accurately weigh 3 mg of DP-2-ZZ-05 reference substance, place it in a 10 mL volumetric flask, add methanol to dissolve and dilute to the scale, shake well, and obtain.
[0078] DP-1 positioning solution: Accurately measure 0.1 mL of DP-1 stock solution (100 times) and place it in a 10 mL volumetric flask, add blank solution to dilute to the scale, shake well, and obtain.
[0079] DP-1-ZZ-02 positioning solution: Accurately weigh 4 mg of DP-1-ZZ-02 reference substance, place it in a 200 mL volumetric flask, add blank solution to dissolve and dilute to the scale, shake well, and obtain.
[0080] DP-2-ZZ-01 positioning solution: Accurately measure 0.1 mL of DP-2-ZZ-01 stock solution (100 times) and place it in a 10 mL volumetric flask. Add blank solution to dilute to the scale and shake well.
[0081] DP-2-ZZ-02 positioning solution: Accurately measure 0.1 mL of DP-2-ZZ-02 stock solution (100 times) and place it in a 10 mL volumetric flask. Add blank solution to dilute to the scale and shake well.
[0082] DP-2-ZZ-03 positioning solution: Accurately weigh 3 mg of DP-2-ZZ-03 reference substance, place it in a 50 mL volumetric flask, add blank solution to dissolve and dilute to the scale, shake well, and obtain.
[0083] DP-2-ZZ-04 positioning solution: Accurately measure 0.1 mL of DP-2-ZZ-04 stock solution (100 times) and place it in a 10 mL volumetric flask, add blank solution to dilute to the scale, shake well, and obtain.
[0084] DP-2-ZZ-05 positioning solution: Accurately measure 0.1 mL of DP-2-ZZ-05 stock solution (100 times) and place it in a 10 mL volumetric flask. Add blank solution to dilute to the scale and shake well.
[0085] Impurity reference substance stock solution (10 times): Accurately weigh 5 mg of DP-1-ZZ-02 reference substance and 15 mg of DP-2-ZZ-03 reference substance, place them in a 25 mL volumetric flask, then accurately measure 2.5 mL each of DP-1 stock solution (100 times), DP-2-ZZ-01 stock solution (100 times), DP-2-ZZ-02 stock solution (100 times), DP-2-ZZ-04 stock solution (100 times) and DP-2-ZZ-05 stock solution (100 times), place them in the same volumetric flask, add purified water to dilute to the scale, shake well, and obtain.
[0086] System suitability solution: Accurately weigh 40 mg of DP-2 and place it in a 20 mL volumetric flask. Accurately measure 2 mL of the impurity reference stock solution (10 times) and place it in the same volumetric flask. Add the blank solution to dissolve and dilute to the scale. Shake well to obtain.
[0087] (2) Experimental methods:
[0088] Accurately measure 10 μL of blank solution, each positioning solution, and system suitability solution, and inject them into the liquid chromatograph respectively, and record the chromatogram. Figure 1 and Figure 2 .
[0089] (3) Requirement: The separation between the main peak and the specific impurity peak and the adjacent peaks should be ≥1.5.
[0090] (4) Results:
[0091] Table 7 System suitability results
[0092]
[0093] Table 8 Specificity results
[0094]
[0095]
[0096] (5) Conclusion: The blank solution had no interference, and the separation between the main peak and the specific impurity peak and the adjacent peaks was ≥1.5. The method had good specificity.
[0097] 2. Limit of quantification (LOQ) and limit of detection (LOD) investigation
[0098] (1) Solution preparation
[0099] Blank solution: Take methanol-purified water (volume ratio of 40:60) as the blank solution.
[0100] Linear stock solution (10 times): accurately weigh 5 mg of DP-2 reference substance, 5 mg of DP-1-ZZ-02 reference substance, and 15 mg of DP-2-ZZ-03 reference substance, respectively, and place them in a 25 mL volumetric flask. Then accurately measure 2.5 mL each of DP-1 stock solution (100 times), DP-2-ZZ-01 stock solution (100 times), DP-2-ZZ-02 stock solution (100 times), DP-2-ZZ-04 stock solution (100 times), and DP-2-ZZ-05 stock solution (100 times), and place them in the same volumetric flask. Add purified water to dilute to the scale, shake well, and obtain.
[0101] Take the linear stock solution (10 times) and prepare the limit of quantification and detection limit solutions respectively. For DP-2-ZZ-01, DP-2-ZZ-02, DP-2-ZZ-05, DP-1, DP-2 and DP-2-ZZ-04, the detection limit is 2.5% and the quantification limit is 10%, and 6 limit of quantification solutions are prepared in parallel; for DP-1-ZZ-02 and DP-2-ZZ-03, the detection limit is 0.25% and the quantification limit is 10%, and 6 limit of quantification solutions are prepared in parallel.
[0102] (2) Experimental methods:
[0103] Accurately measure 10 μL of the detection limit solution and the quantification limit solution, respectively, inject them into the liquid chromatograph, and record the chromatograms.
[0104] (3) Requirements: The S / N ratio of each chromatographic peak at the detection limit concentration is ≥ 3; the S / N ratio of each chromatographic peak at the quantification limit concentration is ≥ 10, and the RSD of the peak areas of the six chromatographic peaks at the quantification limit concentration is ≤ 10.0%.
[0105] (4) Results:
[0106] Table 9 Results of limit of quantitation and limit of detection
[0107]
[0108] Table 10 DP-2 quantitative limit repeatability results
[0109]
[0110]
[0111] Table 11 Repeatability results of quantitation limit of DP-1
[0112]
[0113] Table 12 Repeatability results of quantitation limit of DP-1-ZZ-02
[0114]
[0115]
[0116] Table 13 Repeatability results of quantitation limit of DP-2-ZZ-01
[0117]
[0118] Table 14 Repeatability results of quantitation limit of DP-2-ZZ-02
[0119]
[0120]
[0121] Table 15 Repeatability results of quantitation limit of DP-2-ZZ-03
[0122]
[0123] Table 16 Repeatability results of quantitation limit of DP-2-ZZ-04
[0124]
[0125]
[0126] Table 17 Repeatability results of quantitation limit of DP-2-ZZ-05
[0127]
[0128] (5) Conclusion: The S / N of each chromatographic peak at the detection limit concentration is ≥3; the S / N of each chromatographic peak at the quantification limit concentration is ≥10, and the RSD of the peak areas of the six chromatographic peaks at the quantification limit concentration is ≤10.0%, which can meet the requirements of accurate quantitative detection.
[0129] 3. Accuracy test
[0130] (1) Solution preparation
[0131] Blank solution: Take methanol-purified water (volume ratio of 40:60) as the blank solution.
[0132] DP-2-ZZ-02 stock solution (100 times): Accurately weigh 15 mg of DP-2-ZZ-02 reference substance, place it in a 50 mL volumetric flask, add methanol to dissolve and dilute to the scale, shake well, and obtain.
[0133] Impurity reference substance stock solution (100 times): Accurately weigh 3 mg each of DP-2-ZZ-01 and DP-2-ZZ-05 reference substances, 4 mg of DP-1 reference substance, and 6 mg of DP-2-ZZ-04 reference substance, place them in the same 10 mL volumetric flask, add methanol to dissolve and dilute to the scale, shake well, and obtain.
[0134] Impurity reference substance stock solution (10 times): Accurately weigh 5 mg of DP-1-ZZ-02 reference substance and 15 mg of DP-2-ZZ-03 reference substance, respectively, and place them in a 25 mL volumetric flask. Accurately measure 2.5 mL of impurity reference substance stock solution (100 times) and DP-2-ZZ-02 stock solution (100 times), place them in the same volumetric flask, add 5 mL of methanol to dissolve, add purified water to dilute to the scale, shake well, and obtain.
[0135] Impurity reference solution: Accurately measure 2 mL of the impurity reference stock solution (10 times), place it in a 20 mL volumetric flask, add blank solution to dilute to the scale, shake well, and obtain.
[0136] Test solution: accurately weigh 40 mg of DP-2, place in a 20 mL volumetric flask, add blank solution to dissolve and dilute to scale, shake well, and prepare three times in parallel.
[0137] 10% limit spiked test solution: accurately weigh 40 mg of DP-2 and place it in a 20 mL volumetric flask. Accurately measure 0.2 mL of impurity reference stock solution (10 times) and place it in the same 20 mL volumetric flask. Dissolve the blank solution and dilute to the mark. Shake well to obtain. Prepare three replicates in parallel.
[0138] 50% limit spiked test solution: accurately weigh 40 mg of DP-2 and place it in a 20 mL volumetric flask. Accurately measure 1 mL of the impurity reference stock solution (10 times) and place it in the same 20 mL volumetric flask. Dissolve the blank solution and dilute to the mark. Shake well to obtain. Prepare three replicates in parallel.
[0139] 100% limit spiked test solution: accurately weigh 40 mg of DP-2 and place it in a 20 mL volumetric flask. Accurately measure 2 mL of impurity reference stock solution (10 times) and place it in the same 20 mL volumetric flask. Dissolve the blank solution and dilute to the mark. Shake well to obtain. Prepare three replicates in parallel.
[0140] 150% limit spiked test solution: accurately weigh 40 mg of DP-2 and place it in a 20 mL volumetric flask. Accurately measure 3 mL of impurity reference stock solution (10 times) and place it in the same 20 mL volumetric flask. Dissolve the blank solution and dilute to the mark. Shake well to obtain. Prepare three replicates in parallel.
[0141] Control solution: Accurately measure 0.5 mL of each test solution and 100% limit spiked test solution, place them in different 50 mL volumetric flasks, add blank solution to dilute to the scale, shake well, and obtain.
[0142] (2) Experimental method: Accurately measure 10 μL of the blank solution, impurity reference solution, test solution, each limit spiked test solution, each test solution and the reference solution corresponding to the 100% limit spiked test solution, inject into the liquid chromatograph, record the chromatogram, and calculate the individual recovery rate, total average recovery rate, RSD and total RSD of each impurity at each concentration by the external standard method and the self-control method.
[0143] (3) Requirements: The individual and average recoveries of the impurities in the 10% spiked test solution should be between 70.0% and 130.0%, and the RSD of the recoveries should be ≤20.0%; the individual and average recoveries of the impurities in the 50%, 100%, and 150% spiked test solutions should be between 80.0% and 120.0%, and the RSD of the recoveries of the impurities and the RSD of the total recovery should be ≤10.0%.
[0144] (4) Results:
[0145] Table 18 DP-1 accuracy results (external standard method)
[0146]
[0147] Table 19 DP-1 accuracy results (self-control method)
[0148]
[0149] Table 20DP-1-ZZ-02 accuracy results (external standard method)
[0150]
[0151] Table 21 DP-1-ZZ-02 accuracy results (self-control method)
[0152]
[0153] Table 22DP-2-ZZ-01 accuracy results (external standard method)
[0154]
[0155]
[0156] Table 23 DP-2-ZZ-01 accuracy results (self-control method)
[0157]
[0158] Table 24DP-2-ZZ-02 accuracy results (external standard method)
[0159]
[0160]
[0161] Table 25 DP-2-ZZ-02 accuracy results (self-control method)
[0162]
[0163] Table 26 DP-2-ZZ-03 accuracy results (external standard method)
[0164]
[0165] Table 27 DP-2-ZZ-03 accuracy results (self-control method)
[0166]
[0167] Table 28 DP-2-ZZ-04 accuracy results (external standard method)
[0168]
[0169] Table 29 DP-2-ZZ-04 accuracy results (self-control method)
[0170]
[0171] Table 30DP-2-ZZ-05 accuracy results (external standard method)
[0172]
[0173] Table 31 DP-2-ZZ-05 accuracy results (self-control method)
[0174]
[0175] (5) Conclusion: The recovery rates at each concentration point meet the requirements and the accuracy of this method is good.
[0176] The above is only a preferred embodiment of the present invention and does not limit the present invention in any way. Any simple modification, change and equivalent change made to the above embodiment according to the technical essence of the present invention still falls within the protection scope of the technical solution of the present invention.
Claims
1. A method for analyzing related substances of domperidone intermediate DP-2, characterized in that: The method comprises the following steps: Step 1: Solution preparation: Preparation of diluent: Mix purified water and methanol in a volume ratio of 60:40 to obtain a diluent; Preparation of test solution: Weigh the domperidone intermediate DP-2, dissolve it in diluent and dilute it to make a 2 mg / mL test solution; Preparation of control solution: Accurately pipette the test solution and dilute it with diluent to prepare a control solution containing 20 μg / mL of domperidone intermediate DP-2; Step 2, high performance liquid chromatography determination: accurately measure the test solution and the control solution obtained in step 1, respectively, inject them into the high performance liquid chromatograph for detection, and record the chromatogram. The specific chromatographic conditions are: Chromatographic column: C18; Detection wavelength: 280nm; Mobile phase: ammonium acetate aqueous solution as mobile phase A, methanol as mobile phase B; Flow rate: 0.8mL / min~1.2mL / min; Column temperature: 28℃~32℃; Injection volume: 10 μL.
2. The method for analyzing related substances of a domperidone intermediate DP-2 according to claim 1, characterized in that: The chromatographic conditions in step 2 are: Chromatographic column: Waters XBridge C18, length 250 mm, inner diameter 4.6 mm, filler particle size 5 μm; Detection wavelength: 280nm; Mobile phase: 0.5% ammonium acetate aqueous solution as mobile phase A, methanol as mobile phase B; Flow rate: 1.0 mL / min; Column temperature: 30°C; Injection volume: 10 μL.
3. The method for analyzing related substances of a domperidone intermediate DP-2 according to claim 1, characterized in that: The procedure for detection using gradient elution in step 2 is as follows: 。
Citation Information
Patent Citations
Synthesis method of domperidone drug intermediate 1-(3-chloropropyl)-benzimidazolyl-2-one
CN105439960A
Synthesis method of intermediate 1-(3-chloropropyl)-benzimidazol-2-ketone of domperidone medicine
CN106397333A
Method for synthesizing 1-(3-chloropropyl)-benzimidazole-2-ketone
CN108129396A
